Company Filing History:
Years Active: 2022-2024
Title: Innovations of James Michael McDonnell
Introduction
James Michael McDonnell is a notable inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of anti-IgE antibodies. With a total of 2 patents to his name, McDonnell's work focuses on improving treatments for disorders caused by IgE.
Latest Patents
McDonnell's latest patents revolve around improved anti-IgE antibodies and antigen binding agents. These inventions target IgE for use in treating disorders such as allergic responses and certain autoimmune responses. His work specifically addresses disorders caused by the interaction of IgE with the FcεRI receptor. The improved anti-IgE antibodies may exhibit enhanced affinity for IgE and improved interactions with the Cε2 domain of IgE. Additionally, these inventions aim to disassociate IgE from the FcεRI receptor at pharmaceutically relevant concentrations, providing novel treatments for IgE-mediated disorders.
Career Highlights
James Michael McDonnell is currently associated with Ucbbiopharma Srl, where he continues to innovate in the field of biotechnology. His research has the potential to significantly impact the treatment of allergic and autoimmune disorders.
Collaborations
Some of McDonnell's notable coworkers include Ralph Adams and Thomas Allen Ceska. Their collaborative efforts contribute to the advancement of research in the field of anti-IgE therapies.
Conclusion
James Michael McDonnell's contributions to the development of anti-IgE antibodies represent a significant advancement in biotechnology. His innovative work continues to pave the way for improved treatments for patients suffering from IgE-mediated disorders.